Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.66 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.59 |
| ▸ | INSR | P06213 | 4/20 | 0.59 |
| ▸ | IGF1R | P08069 | 4/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | ROS1 | P08922 | 1/20 | 0.59 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.59 |
| ▸ | PLK1 | P53350 | 1/20 | 0.54 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24179109 | 0.93 | ALK (0.69) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL24178904 | 0.93 | EGFR (0.76) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL24179097 | 0.92 | EGFR (0.62) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL24179124 | 0.87 | ALK (0.74) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL24179130 | 0.86 | ALK (0.67) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL24179308 | 0.86 | EGFR (0.56) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL26528471 | 0.83 | ALK (0.64) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL24179100 | 0.82 | EGFR (0.67) | EGFRALKINSRIGF1R | |
| SCHEMBL24179131 | 0.82 | EGFR (0.65) | EGFRALKINSRIGF1RAURKA | |
| SCHEMBL24179098 | 0.81 | EGFR (0.62) | EGFRALKINSRIGF1RAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322822-A1 | ARYL PHOSPHOROUS OXIDE COMPOUNDS AND USE THEREOF | CHENGDU DI'AO JIUHONG PHARMACEUTICAL FACTORY (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322822-A1 | ARYL PHOSPHOROUS OXIDE COMPOUNDS AND USE THEREOF | CHENGDU DI'AO JIUHONG PHARMACEUTICAL FACTORY (CN) | 2023-10-12 | — | — | US | disclosed |
| EP-4177258-A1 | ARYLPHOSPHINE OXIDE COMPOUNDS AND USE THEREOF | Chengdu Di'Ao Jiuhong Pharmaceutical Factory (CN) | 2023-05-10 | — | — | EP | disclosed |
| WO-2022002241-A1 | ARYLPHOSPHINE OXIDE COMPOUNDS AND USE THEREOF | 成都地奥九泓制药厂 | 2022-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322822-A1 | ARYL PHOSPHOROUS OXIDE COMPOUNDS AND USE THEREOF | ALK, EGFR, ROS1 | EGFR 2/4885ALK 1/4885INSR 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.